Since Blinatumomab, a canonical CD3/CD19 BiTE, was approved by the United States Food and Drug Administration (FDA) in December 2014 for adult Philadelphia chromosome negative (Ph-) relapsed or refractory (R/R) B cell progenitor acute lymphoblastic leukemia (B-ALL), BiTEs for the management of hematologic malignancies have been developed rapidly [3]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.